Evotec received a research grant of up to €2.5 million (about $3.74 million) from the German government to fund R&D on serine racemase, a potential target in the field of neuroprotection. The grant will fund the company’s use of its compound library and fragment-based drug discovery platform to progress the project toward the clinic.
The money was awarded as part of Evotec’s involvement in the German government-supported Neu2 consortium. The consortium is focused on developing therapeutics against neurodegenerative diseases including multiple sclerosis.
Partners include Evotec, Merck Serono, the European ScreeningPort, Bionamics, and the University Medical Center Hamburg-Eppendorf.